Avenue Therapeutics Stock (NASDAQ:ATXI)
Previous Close
$1.89
52W Range
$1.60 - $26.48
50D Avg
$2.27
200D Avg
$5.31
Market Cap
$3.77M
Avg Vol (3M)
$44.43K
Beta
-0.18
Div Yield
-
ATXI Company Profile
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.